Patients with diabetes show poor adherence therapy for heart disease

Adherence to heart disease drugs dopped by half within one year, increasing risks

May 21, 2019

Adherence to add-on therapies for heart disease dropped by half within one year for patients new to diabetes with heart disease, increasing risks for heart attacks or strokes

This study on diabetes looked at members newly diagnosed with diabetes who also had pre-existing cardiovascular disease (ASCVD). Three separate antihyperglycemic drug classes are recommended as add-on therapy for people with diabetes who also have ASCVD.

  • Glucagon like peptide-1 agonists (GLP-1)
  • Sodium-glucose cotransporter-2 inhibitors (SGLT-2i
  • Dipeptidyl peptidase-4 inhibitors (DPP-4i)

All these medications require long-term adherence to reduce complications from ASCVD. But for all the drug classes in the study, adherence dropped off by about half within a year. (Yet the drug manufacturers reported adherence of 90 percent in their clinical trials.)

Read more.

Among Commercially Insured Members with Diabetes Mellitus (DM), Choice and Persistence of Drug Therapy: Dipeptidyl Peptidase-4 Inhibitors (DPP-4i) Versus Glucagon-like Peptide-1 Agonists (GLP-1) or Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) (Fall 2018)

Related news

Perspectives

April 17, 2024

AMCP 2024: Behind the research with YuQian Liu

Ahead of her session with Andy Killpack, Liu — senior director of specialty clinical solutions at Prime/MRx — shares current care management strategies for cell and gene therapy and the future of this exciting frontier

Perspectives

April 16, 2024

AMCP 2024: Behind the research with Jacob LaRue and Timothy O’Shea

Ahead of their session, Jacob and Timothy share how Prime/MRx is working alongside providers like Horizon Blue Cross Blue Shield of New Jersey to manage drug waste and rein in spend for specialty drugs without therapeutic impact to patients

Perspectives

April 15, 2024

Oncology Insights: Cancer treatment is personal

Precision medicine, or personalized medicine, uses genes or proteins to diagnose or treat disease. This medical care design has significantly impacted oncology and grew out of a need to improve and individualize patient treatments